UNSPSC 51241136: Unoprostone isopropyl ester

This classification denotes a prostaglandin analogue and anti-glaucoma agent with the molecular formula C25H44O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5M161S5O5P, chemically known as isopropyl z-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl)hept-5-enoate, d-, but more generally known as unoprostone isopropyl ester, which bears US NIH Compound Identifier 5282175.

European Medicines Agency schedules unoprostone isopropyl ester or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11381MIG. Most nations, for tariff purposes, schedule unoprostone isopropyl ester under HS 29375000. SMILES: CCCCCCCC(=O)CC[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)OC(C)C)O)O.

UNSPSC 51241136 Unoprostone isopropyl ester is a Commodity code covering a specific ophthalmic pharmaceutical — a prostaglandin analog used to treat elevated intraocular pressure and glaucoma. State and local governments procure this drug primarily through health departments, corrections systems, and public hospital networks that maintain formularies for inmates, patients, and beneficiaries requiring topical eye treatment. The drug is typically acquired via standing orders or periodic RFQs as part of broader pharmaceutical inventory management rather than as a standalone procurement event. Issuing bodies include state departments of corrections, state health agencies, county health systems, and municipal hospital procurement offices. Volume and frequency depend on patient census and treatment protocols within each jurisdiction.

The source provided contains no record of recent state and local contract opportunities, addenda, Q&A activity, or posted solicitations under this Commodity code. Without recent bid activity to establish geographic concentration or representative procurement patterns, no issuing-body repeat-buyer profile or regional activity summary can be drawn. A business development professional evaluating this code should monitor procurement portals in corrections and public-health sectors where glaucoma management is a standing clinical need, but current market signals are sparse.